



ASX ANNOUNCEMENT

7 December 2009

Share Purchase Plan Closes Oversubscribed

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has today announced the successful completion of the Share Purchase Plan (SPP), announced on 21 October 2009 (please see **ASX: TIS Share Purchase Plan Announcement**) and approved by shareholders at the Company's Annual General Meeting on 27 November 2009.

The SPP has been substantially oversubscribed and is expected to generate at least \$2.7 million in capital for the Company. New shares under the SPP will be issued at 11.84 cents each.

Due to the oversubscription, Tissue Therapies is working with its Share Registry, Link Market Services, to complete a scale back of shareholder applications. Further information will be released when this process is complete.

Further information:

Dr Steven Mercer

CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic skin ulcers and burns.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com